Nanobiotix's Stock Skyrockets with J&J Partnership for NBTXR3
American depositary receipts of Nanobiotix surged over 50% after the French biotech company signed an agreement with Johnson & Johnson's Janssen Pharmaceutical to co-develop a drug for treating head and neck cancer tumors. Nanobiotix will receive $60 million in the near term, up to $30 million in equity investment by 2027, and potentially up to $1.8 billion in payments based on development, regulatory, and sales milestones. The deal excludes China and certain Asian markets where Nanobiotix has already licensed the drug to LinaBio.